Medscape23h
GLP-1 Reduces Recurrent Ischemic Stroke in Type 2 Diabetes
Liraglutide, a GLP-1 significantly lowers the rate of recurrent stroke in patients with diabetes, with no apparent increase ...
Renal & Urology News18d
Real-World Effectiveness of GLP-1 RA vs DPP4i in Moderate to Severe CKD Explored
The risks for disease progression and death were lower for patients with stage 3b or higher CKD receiving GLP-1 RA vs DPP4i. Real-world data show that treatment with glucagon-like peptide-1 ...
Monthly Prescribing Reference13d
GLP-1 RAs Tied to Higher Thyroid Cancer Risk in First Year of Treatment
The numbers of patients diagnosed with thyroid cancer were 0.17% in the GLP-1 RA group, 0.23% in the DPP4i group, 0.17% in the SGLT2i group, and 0.20% in the sulfonylurea group. (HealthDay News ...
Medscape15h
GLP-1 Therapies for HFpEF: Optimizing Outcomes Through Patient-Centered Care
Dr Pandey shares key insights on dosing, monitoring, and patient education to sustain therapy and improve outcomes. Essential for cardiologists and PCPs!
Renal & Urology News28d
Perioperative GLP-1 RA Use Reduces Risk for Complications in Patients With Diabetes
an active perioperative glucagon-like peptide-1 receptor agonist (GLP-1 RA) prescription is associated with reductions in risk-adjusted readmission, wound dehiscence, and hematoma, according to ...
Yahoo Finance13d
New Truveta study highlights patterns of discontinuation and reinitiation of GLP-1 RA medications
Truveta’s groundbreaking study analyzing real-world use of GLP-1 receptor agonist (GLP-1 RA) therapies in adults with overweight or obesity has published in JAMA Network Open, offering critical ...